FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours ner response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* McCarthy Sean A.						2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX]							(Ch	eck all applic X Directo	r		10% Ov	ner
(Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400						3. Date of Earliest Transaction (Month/Day/Year) 03/31/2021								X Officer (give title below) Other (specify below) President and CEO				
(Street) SOUTH SAN FRANCISCO CA 94080				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	dividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)	D				:4: 8 -				-f D-		. 0				
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/				action	on 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acc Disposed Of (D)		,		5. Amou Securitie Beneficia Owned F	es ally Following	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	ction(s)			(Instr. 4)	
Common Stock 03/31/20				1/2021	21		M		100,000	A	A \$1.1339		306,894		D			
Common Stock 03/31/20				1/2021	21		S ⁽¹⁾		100,000 D \$7.		\$7.4947	206,894			D			
			Table II								posed of, converti			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 a	g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ect (Instr. 4)
					Code	v	(A) (D)		Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Option (Right to Buy)	\$1.1339	03/31/2021			M			100,000	(3)		09/20/2021	Common Stock	100,000	\$0.00	92,14	3	D	

Explanation of Responses:

- 1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- 2. This transaction was executed in multiple trades in prices ranging from \$7.35 to \$7.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 3. 100% of the shares subject to the option are fully vested and exercisable.

/s/ Lloyd Rowland, as Attorney-04/02/2021 in-Fact for Sean A. McCarthy

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.